Clinical Trial Update: Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating safety and efficacy of combining buparlisib (BKM120) with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Buparlisib (BKM120) (buparlisib)
• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED